Brendan Buckley Non-Exec Director Sells 2,017,000 Shares at 8.65p

Go to News Explorer RNS Director/PDMR Shareholding Share this article

Director/PDMR Shareholding

HVIVO PLC Released 18:14:00 24 April 2026 RNS Number : 9139B hVIVO PLC 24 April 2026

hVIVO plc

("hVIVO", the "Company" or the "Group")

Director/PDMR Dealings

London, UK - 24 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, has been notified that Brendan Buckley, Non-Executive Director, has sold 2,017,000 ordinary shares of £0.001 each in the Company ("Ordinary Shares") at a price of 8.65p per Ordinary Share.

Following this transaction, Brendan Buckley, who has informed the Company of his intention not to stand for re-election at the upcoming AGM, now holds 2,000,270 Ordinary Shares in the Company.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

For further information please contact:

| hVIVO plc | | +44 (0)20 7756 1300 |
| Yamin 'Mo' Khan, Chief Executive Officer

Stephen Pinkerton, Chief Financial Officer |

| Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) | +44 (0)20 7220 0500 |
| Geoff Nash, Callum Davidson
Trisyia Jamaludin, Harriet Ward

Nigel Birks - Life Science Specialist Sales

Louise Talbot - Sales |

| Peel Hunt LLP (Joint Broker) | +44 (0)20 7418 8900 | |
| James Steel, Dr Christopher Golden |

| Davy (Joint Broker) | +353 (0) 1 679 6363 | |
| Anthony Farrell, Niall Gilchrist |

| ICR Healthcare (Financial PR & IR)

Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson | | hVIVO@icrhealthcare.com |

Notes to Editors

hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.

The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.

With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.

· Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.

· Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.

· Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in London - the largest of its kind worldwide - to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.

· Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

| 1 | Details of the person discharging managerial responsibilities/person closely associated |
| a. | Name of PDMR | Brendan Buckley |
| 2 | Reason for notification |
| a. | Position/Status | Non-Executive Director |
| b. | Initial notification/

Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a. | Name | hVIVO plc |
| b. | LEI | 213800VT5KBM7JLIV118 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| a. | Description of the financial instrument, type of instrument

Identification Code | Ordinary shares of £0.001 each

ISIN GB00B9275X97 |
| b. | Nature of the transaction | Sale of Ordinary Shares |
| c. | Price(s) and volume(s) | | No. of Shares | Price |
| 2,017,000 | 8.65p | | No. of Shares | Price | 2,017,000 | 8.65p |
| No. of Shares | Price |
| 2,017,000 | 8.65p |
| d. | Aggregated information

• Aggregated Volume

• Price | 2,017,000

8.65p |
| e. | Date of the transaction | 24 April 2026 |
| f. | Place of the transaction | London Stock Exchange, AIM Market (XLON) |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHDZLFLQZLFBBF London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

© 2026 London Stock Exchange plc. All rights reserved.